Novartis iptacopan meets primary endpoints in Phase II study in rare kidney disease C3 glomerulopathy (C3G)

/PRNewswire/ -- Novartis today announced that a Phase II study of investigational iptacopan (LNP023) – a first-in-class, oral, selective factor B inhibitor –...

Related Keywords

Praga ,Praha ,Hlavníesto ,Czech Republic ,United States ,Newcastle Upon Tyne ,United Kingdom ,America ,American ,Julie Masow ,Jamie Bennett ,Edwin Wong ,Sloan Simpson ,John Tsai ,Prnewswire Novartis ,Head Of Global Drug Development ,Twitter ,Novartis ,Exchange Commission ,Newcastle University ,National Kidney Foundation ,National Renal Complement Therapeutics Centre ,Nj Novartis Pharmaceuticals Corporation ,Novartis Pharmaceuticals Corporation ,American Society Of Nephrology Annual Meeting ,American Society Of Nephrology ,Decision Resources Group ,American Society ,Consultant Nephrologist ,Global Drug Development ,Chief Medical Officer ,Novartis Institutes ,Therapy Designation ,East Hanover ,Pharmaceuticals Corporation ,Nephrology Annual Meeting ,Patients Transplanted ,System Part ,Narrative Review ,Rare Renal ,Intj Mol ,Improving Global ,Clinical Findings ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,Trade Show News ,